Highlights from

ACC 2020

Together with World Congress of Cardiology

Virtual 28 - 30 March 2020

Renal denervation better than sham for blood pressure

The SPYRAL PIVOTAL - SPYRAL HTN-OFF MED trial showed that renal denervation was superior to a sham procedure at reducing blood pressure in patients with uncontrolled high blood pressure at 3 months follow-up.

Prof. Michael Böhm (Saarland University Medical Center, Germany) presented the international, prospective, single-blinded, sham-controlled trial, which was designed to assess the efficacy of renal denervation in the absence of antihypertensive medications [1]. The findings were simultaneously published in The Lancet [2].

This trial was instigated based on observational data suggesting that catheter-based renal denervation significantly reduced blood pressure. Following a positive pilot trial, the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED trial was powered to evaluate the efficacy of catheter-based renal denervation in the absence of medications. Participants (n=331) from 46 sites had a systolic blood pressure (average over 24 hours) between 140 -170 mmHg and had either never taken any blood pressure-reducing medications or had discontinued those medications for at least 3 weeks prior to study entry. Characteristics were similar between both groups; 67% were men, the average age was 53, and the average body mass index was 31. Patients were randomised to either renal denervation (n=166) or a sham procedure (n=165), during which a catheter was inserted and angiography was performed.

The primary efficacy endpoint was the change in average 24-hour systolic blood pressure at 3 months post-procedure, adjusted for systolic blood pressure at study entry. The secondary efficacy endpoint was the change in average blood pressure measured in the doctor’s office at 3 months, adjusted for office blood pressure at study entry. Major adverse safety events were also assessed at 3 months, including rates of death, stroke, changes in kidney function, or any injury to the arteries surrounding the kidney.

Both endpoints were met. At 3 months, a significant 4.7 mmHg reduction was observed in patients’ 24-hour systolic ambulatory blood pressure and a 9.2 mmHg reduction in office systolic blood pressure. Change in 24-hour systolic blood pressure was 3.9 mmHg (P<0.001) and change in office systolic blood pressure at was 6.6 mmHg (P<0.001; see Figure). No deaths, strokes, or decreases in kidney function occurred during the first 3-months of follow-up.

Prof. Böhm concluded: “The findings show that renal denervation lowers blood pressure not just during the day but also through the night and early morning periods when risk is highest for clinical events and the effect of some medications on blood pressure is reduced. This study establishes renal denervation as an additional option beyond exercise or lifestyle modification for patients with high blood pressure who are unwilling to take or cannot tolerate medication.”

Results from a companion study, the SPYRAL HTN-ON MED trial, which is testing the safety and effectiveness of renal denervation in patients who are taking up to 3 blood pressure-reducing medications, are expected at the end of 2021.

Keywords: SPYRAL PIVOTAL - SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, renal denervation, sham, blood pressure.

Figure: Primary analysis of blood pressure at 3 months over 24-hours at home or the office [1]

Figure- Primary analysis of blood pressure at 3 months

DBP, diastolic blood pressure; RDN, renal denervation; SBP, systolic blood pressure. Figure kindly provided by Prof. Blöm.

  1. Böhm M, et al. Abstract 406-15. ACC/WCC 28-30 March 2020.
  2. Böhm M, et al. Lancet 2020;Mar 29. DOI: 10.1016/S0140-6736(20)30554-7.

Top image: @ iStockPhoto: MStudioImages

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.